Table 1.
Patient Characteristics
| Autologous HSCT | URD HSCT | p-Value | |
|---|---|---|---|
| Number | 101 | 159 | ----- |
| Age | 28.0 years (18 -51) | 27.4 years (18 – 51) | 0.58 |
| Sex (Male%/Female %) | 67/33 | 62/38 | 0.352 |
| Disease Status at HSCT: | CR1 = 64 (63%) | CR1 = 76 (48%) | 0.014 |
| CR2 = 37 (37%) | CR2 = 83 (52%) | ||
| Time from Dx to HSCT (1CR): | 6.2 months (2 - 40) | 7.5 months (4 – 30) | 0.048 |
| Duration of 1CR (2CR): | 31 months (6-111) | 19 months (6-115) | 0.33 |
| Disease Lineage: | |||
| B-cell | 53 (52%) | 66 (42%) | 0.032 |
| T-cell | 21 (21%) | 25 (16%) | |
| Unclassified | 27 (27%) | 68 (43%) | |
| WBC >= 50,000/uL at Dx: | 24 (14%) | 34 (21%) | 0.036 |
| < 50,000/uL | 69 (68%) | 83 (52%) | |
| Missing | 18 (18%) | 42 (26%) | |
| Karyotype: | |||
| High-risk | 17 (17%) | 44 (28%) | 0.066 |
| Normal | 24 (24%) | 21 (13%) | |
| Other | 16 (16%) | 23 (14%) | |
| Unknown | 44 (44%) | 71 (45%) | |
| Recipient CMV Seropositive: | 45 (45%) | 59 (37%) | 0.232 |
| Conditioning: | |||
| TBI + Cy +/- other | 52 (51%) | 144 (91%) | <0.0001 |
| Bu + Cy +/- other | 40 (40%) | 15 (9%) | |
| Other or unspecified | 9 (9%) | ------ | |
| HLA-matching (A, B, DRB1) | |||
| Class I and II match | ------ | 136 (86%) | |
| Class I mismatch | ------ | 2 (1%) | |
| Class II mismatch | ------ | 18 (11%) | |
| Class I and II mismatch | ------ | 1 (1%) | |
| Missing | ------ | 2 (1%) | |
| Graft Manipulation: | |||
| T-cell depletion | ------ | 31 (19%) | |
| Purged ex-vivo | 45 (45%) | ------ | |
| Date of HSCT: | |||
| 1989 – 1995 | 76 (75%) | 42 (42%) | <0.0001 |
| 1996 – 1998 | 25 (25%) | 93 (58%) | |
| Median follow-up (months) | 74 (12-141) | 84 (36-170) |
Legend: HSCT = hematopoietic stem cell transplant; URD = unrelated donor; CR1 = first complete remission; CR2 = second complete remission; WBC = white blood cell count; Dx = diagnosis; CMV = cytomegalovirus. TBI = total body irradiation; Cy = cyclophosphamide; Bu = busulfan; HLA = human leukocyte antigen.